Several other research analysts have also recently issued reports on the stock. Royal Bank of Canada reiterated a hold rating and set a $10.00 target price on shares of Teva Pharmaceutical Industries in a report on Thursday, August 8th. Cowen set a $9.00 target price on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Wednesday, August 7th. UBS Group set a $8.00 price target on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a report on Friday, August 16th. BMO Capital Markets lowered their price target on shares of Teva Pharmaceutical Industries from $11.00 to $9.00 and set a market perform rating for the company in a research report on Friday, August 9th. Finally, Wells Fargo & Co lowered their price target on shares of Teva Pharmaceutical Industries from $17.00 to $8.00 and set a market perform rating for the company in a research report on Monday, September 30th. Five investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $10.64.
Shares of TEVA stock traded up $0.09 during mid-day trading on Tuesday, hitting $9.92. The stock had a trading volume of 11,074,047 shares, compared to its average volume of 17,221,416. Teva Pharmaceutical Industries has a 12-month low of $6.07 and a 12-month high of $20.34. The firm has a market capitalization of $10.93 billion, a P/E ratio of 3.54, a price-to-earnings-growth ratio of 1.12 and a beta of 1.82. The firm’s 50-day moving average is $9.16 and its two-hundred day moving average is $8.35. The company has a debt-to-equity ratio of 1.62, a current ratio of 0.89 and a quick ratio of 0.56.
In other news, VP Hafrun Fridriksdottir sold 4,310 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.49, for a total value of $45,211.90. Following the sale, the vice president now directly owns 24,883 shares in the company, valued at approximately $261,022.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 18,033 shares of company stock worth $102,261 over the last 90 days. Company insiders own 0.49% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. NEXT Financial Group Inc boosted its position in shares of Teva Pharmaceutical Industries by 384.8% in the 2nd quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock worth $39,000 after purchasing an additional 3,394 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in Teva Pharmaceutical Industries by 14.7% in the second quarter. Daiwa Securities Group Inc. now owns 40,583 shares of the company’s stock worth $375,000 after acquiring an additional 5,200 shares in the last quarter. Hartford Investment Management Co. grew its stake in shares of Teva Pharmaceutical Industries by 6.6% during the second quarter. Hartford Investment Management Co. now owns 28,324 shares of the company’s stock worth $261,000 after acquiring an additional 1,748 shares during the last quarter. Strs Ohio grew its stake in shares of Teva Pharmaceutical Industries by 1,909.4% during the second quarter. Strs Ohio now owns 1,651,700 shares of the company’s stock worth $15,245,000 after acquiring an additional 1,569,500 shares during the last quarter. Finally, PGGM Investments grew its stake in shares of Teva Pharmaceutical Industries by 6.3% during the second quarter. PGGM Investments now owns 1,613,034 shares of the company’s stock worth $14,888,000 after acquiring an additional 95,000 shares during the last quarter. 54.10% of the stock is currently owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Further Reading: What is net income?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.